Loading
RT
Revance Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Foley Mark J, was filed 08 Mar 2024.
Revance Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Revance Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of Revance Therapeutics, Inc. in twelve months, the latest record being from 6 February 2025.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
144
Thresholds
n/a
Buy Volume
€1M
4 ops. · all time
Sell Volume
€5M
19 ops. · all time
Who traded when
BuySaleDavid Hollander1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$201.5M
Net income-US$279M-138.4% margin
Last declaration on 6 February 2025
Declarations144 total
97,999 shares@ US$3.6526.6% of flowCommon StockSEC:0000950170-25-015362:0
9,733 shares@ US$3.6569.0% of flowCommon StockSEC:0000950170-25-015359:0
30,106 shares@ US$3.65100.0% of flowCommon StockSEC:0000950170-25-015688:0
28,606 shares@ US$3.65100.0% of flowCommon StockSEC:0000950170-25-015339:0
28,606 shares@ US$3.65100.0% of flowCommon StockSEC:0000950170-25-015341:0
5,784 shares@ US$3.65100.0% of flowCommon StockSEC:0000950170-25-015343:0
47,815 shares@ US$3.6513.9% of flowCommon StockSEC:0000950170-25-015361:0
16,675 shares@ US$3.65100.0% of flowCommon StockSEC:0000950170-25-015354:0
6,922 shares@ US$3.6574.1% of flowCommon StockSEC:0000950170-25-015356:0
16,561 shares@ US$3.6558.6% of flowCommon StockSEC:0000950170-25-015353:0
996,935 shares@ US$3.6537.5% of flowCommon StockSEC:0000950170-25-015363:0
36,506 shares@ US$3.6542.0% of flowCommon StockSEC:0000950170-25-015322:0
6,888 shares0Common StockSEC:0000950170-25-014824:0
5,979 shares0Common StockSEC:0000950170-25-014823:0
27,933 shares0Common StockSEC:0000950170-25-014825:0
1,000 shares@ US$2.18450.2% of flowCommon StockSEC:0001479290-25-000005:0
1,000 shares@ US$2.18450.0% of flowCommon StockSEC:0001479290-25-000004:0
3,908 shares@ US$4.1731.0% of flowCommon StockSEC:0001479290-24-000130:0
1,000 shares@ US$2.18450.2% of flowCommon StockSEC:0001479290-24-000103:0
1,000 shares@ US$2.18450.0% of flowCommon StockSEC:0001479290-24-000104:0
15,000 shares0Common StockSEC:0001479290-24-000085:0
15,000 shares0Common StockSEC:0001479290-24-000087:0
15,000 shares0Common StockSEC:0001479290-24-000088:0
15,000 shares0Common StockSEC:0001479290-24-000084:0
15,000 shares0Common StockSEC:0001479290-24-000086:0
25 of 144 declarations
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a U.S.-based biotechnology and specialty aesthetics company that was historically listed on the U.S. market, with shares traded on the NASDAQ/NYSE ecosystem before the company was acquired. Its headquarters are in Nashville, Tennessee, United States. For French-speaking investors evaluating the name, Revance built its profile around differentiated aesthetic medicine and botulinum-toxin-based therapeutics, combining an R&D-heavy business model with a commercial platform focused on injectables and skincare-related products. The company traces its origins back to 1999, when it was founded as Essentia Biosystems and later became Revance Therapeutics. Over time, it evolved from a research-driven development organization into a commercial-stage company with a broader aesthetics and therapeutics portfolio.
Revance’s core business centered on two primary product lines. The flagship product is DAXXIFY® (daxibotulinumtoxinA-lanm), a neuromodulator first approved for glabellar lines and later expanded into cervical dystonia in adults. The company also commercialized the RHA® Collection of dermal fillers in the United States, giving it an important position in the facial aesthetics category. In investor terms, this created a more balanced portfolio: one brand in the botulinum-toxin segment and another in dermal fillers, both aimed at practitioners in aesthetic medicine. Revance also pursued international and partnership-based opportunities, reflecting a strategy to extend the commercial life of its platforms beyond the U.S. market.
Read moreShow less
From a competitive standpoint, Revance operated in a highly concentrated market dominated by much larger players with strong brands, established physician relationships, and global scale. Its strategy was therefore based on differentiation rather than breadth: product formulation, clinical profile, duration of effect, and targeted commercial execution. DAXXIFY was positioned as an innovation in neuromodulator formulation, while the RHA Collection offered a complementary filler portfolio in a category where brand loyalty and injector preference matter significantly. That combination gave Revance a credible, though niche, market position in medical aesthetics.
Recent developments are material. In February 2025, Crown Laboratories completed its acquisition of Revance and the combined business was rebranded as REVANCE, with Nashville as the headquarters. Prior to that transaction, Revance had been reporting continued commercial rollout of DAXXIFY and the RHA Collection, including expansion into therapeutics. The acquisition is the key strategic event that changed the company’s public-market story: investors should now view Revance less as an independent listed biotech and more as a legacy brand and product platform folded into a privately held skincare and aesthetics group in the United States.
